Loading…
← CockpitCompetitor Analysis › CLYM Climb Bio, Inc.Open in the cockpit ↗

Climb Bio, Inc.CLYMCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 18
Mkt cap
$546M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$12.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
110 days
8 Mar 2027
Close · USD$9.30
1D-4.9%
1W-24.1%
1M-13.9%
3M-45.4%
6M-11.6%
YTD+132.5%
1Y+394.7%
ATR %10.0%
Beta1.59
52w lowhigh49.3% off high

What Climb Bio does

Employees: 28

Climb Bio at a glance

Size Climb Bio (CLYM) is a United States Health Care company (Biotechnology) with a market value of $546M, the 2610th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.30 on 18 Nov 2026.

Performance Over six months the shares fell 11.6%, against -19.4% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 19 in its peer set.

Short interest Short interest is 18.1% of the free float (30 Oct 2026).

Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026CLYM 85Peer median 81
Six months, rebased to 100: Climb Bio against the median of its 20 peers (local-currency closes).

Climb Bio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$296,000-$97,000$0$0$0
EBITDA-$66.5M-$67.8M-$27.0M-$40.3M-$45.1M
Net income-$59.3M-$59.9M-$73.9M-$35.1M-$45.2M
Free cash flow-$53.6M-$54.5M-$15.6M-$20.6M-$37.4M
Capital expenditure$1.08M$186,000$0$0$0
Total debt$1.07M$541,000$532,000$349,000$480,000

Quarterly statements and history in the cockpit →

Climb Bio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%WVE1521300871SANA300404GNFT1672300318FDMT300858688247SRZN6586CBIOCLYM6-month return →1-month return →
Up and to the right = strong over both horizons. Climb Bio is the large dot.

Climb Bio competitors and peer comparison

How Climb Bio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Climb Bio against its 20 peers (data as of 18 Nov 2026)
MeasureCLYMPeer medianRank in peer set
1-month return-13.9%-15.3%10th highest of 21
6-month return-11.6%-19.4%8th highest of 19
Distance from 52-week high-49.3%-48.1%11th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a

Questions

Which companies are Climb Bio's closest peers?
The cockpit's peer set: Wave Life Sciences (WVE), Frontage (1521.HK), Hvsen Biotechnology (300871.SZ), Sana Biotechnology (SANA), Boji Medical Technology (300404.SZ), Genfit (GNFT.PA), Ascletis Pharma (1672.HK), Beijing Bohui Innovation Biotechnology (300318.SZ).
How has Climb Bio stock performed?
Over six months to 18 Nov 2026 the shares returned -11.6% against -19.4% for the median peer; over one year +394.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.